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Summary:  In this study, we combine genomic data with comprehensive epidemiological data on 
sexual exposure and travel to describe the spread of multidrug-resistant Shigella lineages within 
sexual networks of MSM in Australia, and identify a global outbreak of a multidrug-resistant plasmid.
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ABSTRACT 
Background 
In urban Australia, the burden of shigellosis is either in returning travellers from shigellosis-endemic 
regions, or in men who have sex with men (MSM). Here, we combine genomic data with 
comprehensive epidemiological data on sexual exposure and travel to describe the spread of 
multidrug-resistant Shigella lineages. 
Methods  
A population-level study of all cultured Shigella isolates in the state of Victoria, Australia was 
undertaken from 1 January 2016 through to 31 March 2018. Antimicrobial susceptibility testing, 
whole genome sequencing (WGS) and bioinformatic analysis of 545 Shigella isolates was performed 
at the Microbiological Diagnostic Unit Public Health Laboratory (MDU PHL). Risk factor data on 
travel and sexual exposure were collected through enhanced surveillance forms or by interview.   
Results 
Rates of antimicrobial resistance were high, with 17.6% (95/541) and 50.6% (274/541) resistance to 
ciprofloxacin and azithromycin, respectively. There were strong associations between antimicrobial 
resistance, phylogeny and epidemiology; specifically, two major MSM-associated lineages were 
identified, a S. sonnei lineage (n=159) and a S. flexneri 2a lineage (n=105).  Of concern, 147/159 
(92.4%) of isolates within the S. sonnei MSM-associated lineage harboured mutations associated with 
reduced susceptibility to recommended oral antimicrobials, namely azithromycin, trimethoprim-
sulfamethoxazole and ciprofloxacin. Long-read sequencing demonstrated global dissemination of 
multidrug-resistant plasmids across Shigella species and lineage, but predominantly associated with 
MSM isolates. 
Conclusions 
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Our contemporary data highlight the ongoing public health threat posed by resistant Shigella, both in 
Australia and globally.  Urgent multidisciplinary public health measures are required to interrupt 
transmission and prevent infection.   
Keywords: Shigellosis; epidemiology; genomics; antimicrobial resistance; sexually-transmitted 
infections. 
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INTRODUCTION 
Shigellosis is estimated to cause 190 million cases of diarrhoea globally per year [1].  In low- and 
middle-income countries, the burden of shigellosis is concentrated in children, with inadequate 
sanitation and contaminated food and / or water the most common mode of acquisition. In contrast, 
shigellosis in high-income countries occurs predominantly in returning travellers, or in men who have 
sex with men (MSM) [2, 3].  In many high-income countries there are increasing reports of locally-
acquired shigellosis in MSM, with endemic shigellosis in males in these countries often considered a 
sexually-transmitted infection (STI) [2, 4-8].   
 
As in other countries, treatment for shigellosis in Australia is recommended, to reduce both symptoms 
and asymptomatic bacterial shedding. The recommended first-line oral treatment is ciprofloxacin, and 
as second-line agents, azithromycin or trimethoprim-sulfamethoxazole (co-trimoxazole) [1]. 
However, recent studies have highlighted increasing resistance to these agents amongst Shigella spp., 
in low, middle-income and high-income countries [9-13]. Indeed, the World Health Organisation 
(WHO) and Centers for Disease Control and Prevention (CDC) have declared antimicrobial-resistant 
(AMR) Shigella spp., a major public health threat [14, 15]. Of further concern is a recent advisory 
from the CDC suggesting that ciprofloxacin may not be suitable for treatment in Shigella isolates with 
minimum inhibitory concentrations (MICs) of 0.12–1.0 g/mL [16]. Although current interpretive 
criteria categorise isolates with MICs ≤1.0 g/mL as susceptible [17], this advisory suggested isolates 
with MICs of 0.12–1.0 g/mL may harbour ≥1 mutations associated with fluoroquinolone resistance, 
which could lead to adverse clinical outcomes and sustained shedding if fluoroquinolones are used for 
treatment [16].  Further, there are increasing reports of azithromycin resistance in Shigella spp., 
(mainly amongst MSM in urban populations) where azithromycin resistance is largely mediated by 
the plasmid-encoded mph(A) gene [9, 10, 13].   
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Whole genome sequencing (WGS) has been previously used to describe both the global and regional 
molecular epidemiology of shigellosis. To date, studies have predominantly assessed either the 
population structure of individual Shigella lineages [18, 19], or have focused on representative 
subsamples of epidemiologically-suspected epidemics [9, 10, 20].  Unbiased WGS of all cultured  
Shigella isolates in a population could provide valuable insights into possible transmission networks 
of shigellosis, in addition to providing information on emerging genotypic AMR patterns.  
Accordingly, we performed WGS of all cultured Shigella isolates in the state of Victoria, Australia 
over a two-year period. We combine genomic data with comprehensive epidemiological data on 
sexual exposure and travel to demonstrate the spread of highly-resistant Shigella lineages within 
MSM. Further, we contextualised our isolates with data from recent studies of shigellosis in MSM 
and travellers, and demonstrate global dissemination of highly-related, multi-drug resistant (MDR) 
plasmids.  
 
METHODS 
Setting, bacterial isolates and microbiological testing 
In Australia, shigellosis is a notifiable disease under public health legislation, and diagnostic 
laboratories forward Shigella isolates to a reference laboratory. The Microbiological Diagnostic Unit 
Public Health Laboratory (MDU PHL) is the bacteriology reference laboratory for the state of 
Victoria, covering a resident population of approximately 6.24 million people.  Here, we conducted a 
retrospective, observational study of all cases of shigellosis associated with a Shigella isolate in 
Victoria between January 1
st
 2016 and March 31
st
 2018.   Susceptibility testing was performed as 
detailed in the Supplementary Methods. We classified isolates with a ciprofloxacin MIC of 0.12 – 1 
g/mL as ‘high resistance potential’ (HRP) isolates [21].  
 
Epidemiological investigation 
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Where possible, all cases of shigellosis in Victoria are interviewed by a public health officer (PHO), 
or notifying medical practitioners complete an enhanced surveillance questionnaire. Exposure 
information is collected for the two weeks prior to illness onset. Primary risk factors were considered 
in one of three main categories: (i) male to male sexual contact within Australia; (ii) international 
travel-associated, or (iii) other / unknown risk factor. Cases were classified as unknown source only 
when no risk factors were identified after interview. Travel destinations were categorised using the 
Standard Australian Classification of Countries, 2nd edition [22]. Information on shigellosis 
notifications in Victoria was obtained from the National Notifiable Diseases Surveillance System 
(NNDSS) (http://www9.health.gov.au/cda/source/cda-index.cfm). Data were collected in accordance 
with the Victorian Public Health and Wellbeing Act 2008 [23] and formal ethical approval was not 
required as this work was part of enhanced epidemiological surveillance. 
 
Whole genome sequencing and bioinformatic analysis 
DNA extraction and WGS of study isolates was performed at MDU PHL (Supplementary Methods). 
In brief, reads were aligned to a reference genome to identify single nucleotide polymorphisms 
(SNPs) using Snippy v4.3.5 (https://github.com/tseemann/snippy), with filtering of phage regions 
identified using Phaster  [24] and recombinant regions identified using Gubbins v2.3.4 [25]. The final 
core SNPs were extracted with SNP-sites [26].  
 
A maximum likelihood phylogeny was produced using IQ-tree (v1.6.5) [27] and population structure 
investigated using hierarchical Bayesian Analysis of Population Structure (BAPS) [28]. For context, 
we included data from other WGS-based studies of Shigella [10, 19, 29, 30]. We specifically included 
these previous studies as the epidemiological context (MSM and / or travel) was similar to our study.  
De novo assembly was performed using Unicycler (v.0.4.6) [31], and AMR genes were detected using 
ABRicate (https://github.com/tseemann/abricate).  Point mutations in the quinolone resistance 
determining region (QRDR) were detected by read-mapping (Supplementary Methods). Four 
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genomes were selected for PacBio long read sequencing (details in Supplementary Methods). 
Sequencing data are available at the National Center for Biotechnology Information (NCBI) Short 
Read Archive (SRA) (BioProject PRJNA319594). 
Statistical analysis 
Comparisons between isolates or clusters were made using a chi-squared test. The Mann-Whitney 
Rank sum test was used to compare non-normal distributions.  All statistical analyses were performed 
using R (version 3.4.0). 
 
RESULTS 
Epidemiological characteristics of cases and antimicrobial susceptibility patterns 
In total, 545 Shigella isolates (364 S. sonnei and 181 S. flexneri) isolates underwent WGS, 
representing 42.9% (545/1,269) of shigellosis notifications in Victoria over the study period. The 
median age was 35 years (interquartile range, IQR 27-48, range 0-83), with a male to female ratio of 
2.4 : 1.0 (Supplementary Figure 1). Over one-third of cases (36.0%; 196/545) were associated with 
overseas travel as a primary risk factor, and 176 (32.3%) cases identified MSM as a primary risk 
factor. 541 isolates underwent susceptibility testing (Supplementary Table 1). Decreased 
susceptibility to azithromycin was identified in 51.4% (93/181) of S. flexneri and 50.3% (181/360) of 
S. sonnei (P = 0.81), and resistance to ciprofloxacin in 9.4% (17/181) of S. flexneri and 21.7% 
(78/360) of S. sonnei (P < 0.001).  S. sonnei isolates were significantly more likely to be resistant to 
two or three oral antimicrobials than S. flexneri (62.2% vs 40.9%, P < 0.001 and 6.9% vs 0.6%,  P < 
0.001, respectively) (Supplementary Table 1).  
 
Correlation of phylogeny with epidemiological risk factors for resistant Shigella spp. 
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Isolates were interrogated phylogenetically by species, and clustering was assessed using BAPS. 
Amongst S. sonnei, four major BAPS groups were identified (BP1 – BP4; Table 1) (Figure 1 and 
Supplementary Figures 2-3). An additional cluster (BP5) represented grouping of the most divergent 
isolates, a known limitation of this clustering approach [28]. As such, we did not consider this a 
biologically relevant grouping, and this group was excluded from further analyses. 
 
Correlating the phylogeny with epidemiological characteristics revealed clear links with risk factors. 
Specifically, cases in BP1, BP2 and BP4 were associated with overseas travel (Table 1, 
Supplementary Figure 2), with strong associations between sub-lineages and region of acquisition. 
For example, of the 32 cases of S. sonnei reporting travel to Southern / Central Asia, 32 cases (100%) 
were associated with BP1 (Supplementary Figure 4).  In keeping with this observation, isolates from 
BP1 clustered with representative isolates from the Asian ciprofloxacin-resistant S. sonnei lineage III, 
previously described by Chung et al [19].  Further, in the BP1 lineage, isolates were significantly 
associated with ciprofloxacin resistance (Figure 1 and Table 1); of the 75 ciprofloxacin-resistant 
isolates in BP1, 74 isolates harboured triple mutations in the QRDR (Figure 1).  
 
In contrast to travel-associated lineages, S. sonnei cases in BP3 were significantly associated with 
MSM, with 61% (97/159) of males in this lineage reporting MSM as a primary risk factor (Figure 1 
and Table 1).  Isolates in BP3 were highly related, with a median pairwise core SNP distance of 4 
(IQR 2-6) (Table 1; Supplementary Figure 3A).  Further, MSM cases in BP3 were distributed across 
the study period and not limited to a temporally-restricted outbreak (Supplementary Figure 2). Most 
isolates in BP3 (139/159; 87%) harboured highly-related plasmids (see below) containing AMR 
determinants for azithromycin, trimethoprim and sulfonamides (Figure 1).  Although isolates in this 
lineage were not associated with ciprofloxacin resistance at the current CLSI breakpoint of 1 g/mL, 
reducing the breakpoint to 0.12 g/mL resulted in 147/149 (99%) of tested isolates being re-classified 
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as having HRP for ciprofloxacin.  All 149 isolates harboured single mutations in the QRDR (147 gyrA 
S83L, and 2 gyrA D87Y) (Figure 1).   
 
Amongst S. flexneri, there were four major BAPS groups (BP1 – BP4) (Table 2; Supplementary 
Figure 3).  These groups broadly correlated with serotyping, with the largest group (BP2) 
corresponding to S. flexneri serotype 2a (Supplementary Dataset). An additional cluster (BP5), 
represented grouping of divergent isolates, was excluded from further analyses. Similar to S. sonnei, 
there were distinct associations between phylogeny, AMR and risk factors. Specifically, MSM status 
was associated with BP2 (58.4% (52/89) of males in this lineage were MSM), and to a lesser extent, 
BP1 and BP3 (Table 2), whilst BP4 was more associated with recent travel (Table 2; Figure 2).  In 
contrast to the major BP3 MSM-lineage in S. sonnei, the BP2 MSM-lineage in S. flexneri was not 
associated with ciprofloxacin resistance at a lower breakpoint of 0.12 g/mL, and did not harbour 
QRDR mutations (Figure 2, Supplementary Dataset).  However, 63.8% (67/105) of isolates in the 
BP2 MSM-lineage of S. flexneri harboured azithromycin resistance plasmids similar to those in the S. 
sonnei BP3 MSM- lineage (see below) (Figures 2 & 3). 
 
For context, we undertook combined analyses of 691 S. sonnei isolates (364 Australian and 327 
international) and 408 S. flexneri (171 Australian, 237 international) (Supplementary Figures 4 and 5).  
For both Australian and the United Kingdom (UK) S. sonnei and S. flexneri, there was limited 
clustering of isolates according to region of travel (Supplementary Figures 4-5).  Australian S. sonnei 
MSM isolates in BP3 formed a distinct lineage, almost completely comprising Australian isolates 
(Supplementary Figure 4).  In contrast, for S. flexneri, international serotype 2a isolates in the 
previously described MSM clades from Baker et al. [10] clustered together in the phylogeny with 
Australian isolates in the MSM-associated BP2 lineage (Supplementary Figure 5). Moreover, 31 of 
these international S. flexneri isolates also harboured pKSR100 plasmids, similar to those described 
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from the UK (see below and Figure 3), further suggesting intercontinental dissemination of the MSM-
associated S. flexneri 2a lineage. 
 
Global dissemination of MDR plasmids across Shigella species and lineage 
To understand the relatedness of multi-resistant plasmids in our study, specifically amongst MSM-
associated isolates, long-read sequencing was performed on four genomes, representing S. flexneri 
BP1 and BP2 and S. sonnei BP1 and BP3 (Supplementary Dataset).  All four plasmids harboured 
blaTEM-1, ermB and mph(A), and three of the plasmids contained an integron with additional AMR 
genes, namely sul1, dfrA17 and aadA5 (Figure 3).  Comparison with pKSR100 (a conjugative plasmid 
previously identified in MSM-associated Shigella in the UK [7, 10]) revealed a high level of 
homology between pKSR100 and all four plasmids, (Figure 3).  The global relationship of pKSR100 
plasmids was further explored by comparing all pKSR100-like plasmids (from our study and other 
recent work [10, 13]) to pKSR100 (Figure 4).  pKSR100-like plasmids were disseminated across 
Shigella species but were predominantly associated with MSM-associated shigellosis in both 
Australia and overseas (Figure 4).  
 
DISCUSSION 
In this study, we demonstrate that local and global dissemination of clinically significant AMR 
Shigella spp., is driven largely by the spread of highly-related, multi-resistant plasmids that are not 
restricted by Shigella species or lineage.  By sampling all isolates in a population (rather than 
representatively sub-sampling known outbreaks), and integrating with epidemiological data, we 
identified distinct correlations between Shigella sublineages and the two major modes of shigellosis 
acquisition in high-income countries, namely international travel and domestically-acquired MSM-
associated shigellosis, each associated with approximately one-third of all cases in this study.  
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Of specific concern was the high prevalence of resistance to oral agents currently recommended for 
the treatment of shigellosis.  Approximately 50% of all isolates displayed resistance to azithromycin, 
representing to date, the highest reported azithromycin resistance rate in Shigella spp. globally [13, 
32, 33].  Notably, azithromycin resistance was significantly more common in MSM-associated 
Shigella (93% in BP3 S. sonnei and 71% in BP2 S. flexneri), signalling the demise of azithromycin as 
a suitable treatment option for domestically-acquired shigellosis in MSM in our population. The 
reasons for this high rate of azithromycin resistance are multifactorial, and likely related to both host 
and pathogen factors.  First, the recommended use of azithromycin as an empiric agent for the 
syndromic treatment of urethritis is likely to have exerted selection pressure for the emergence of 
azithromycin-resistance in MSM [34], a hypothesis corroborated by the contemporaneous emergence 
of azithromycin resistance in other sexually-transmitted pathogens such as Neisseria gonorrhoeae, 
Treponema pallidum and Mycoplasma genitalium [35-38].  Second, the finding that mph(A) was 
harboured on genetically similar pKSR100-like plasmids regardless of species or lineage highlights 
the apparent ease of horizontal transmission of these particular plasmids, an observation supported by 
the identification of similar plasmids from multiple geographic locations and epidemiological 
contexts [7, 9, 10, 13]. Collectively, our data support the existence of a global outbreak of a highly 
successful azithromycin resistance plasmid, predominantly in MSM populations.  
 
Compared to azithromycin resistance, ciprofloxacin resistance was largely associated with 
international travel to areas of high endemicity (particularly South East and Central Asia), rather than 
local populations, in keeping with the fact that ciprofloxacin is a restricted antibiotic in Australia [39]. 
However, when an MIC threshold of 0.12 g/mL was applied, approximately 57% of all tested 
isolates in our study were classified as HRP, compared to only 18% at the current resistance 
breakpoint of >1.0 g/mL.  The difference was largely driven by the MSM-associated S. sonnei BP3 
lineage, in which all HRP isolates harboured single mutations (mainly gyrA S83L) in the QRDR. This 
finding is of specific concern given: (i) the sequential development of resistance in the QRDR, in 
which the gyrA S83L mutation is a first step [12], and (ii) the concurrent high prevalence of 
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azithromycin resistance in MSM-associated shigellosis, which may increase therapeutic use of 
ciprofloxacin, leading to a detrimental ‘Catch 22’ situation of ciprofloxacin use further driving 
resistance in this population.   Future work should closely monitor clinical outcomes associated with 
such cases, and indeed, recent guidelines suggest that antimicrobial treatment should now only be 
reserved for ‘high-risk’ populations (e.g. immunocompromised patients; the very young or elderly, 
and individuals at risk of causing outbreaks, such as food handlers or childcare workers) [21].   
 
Given our finding of several travel-associated cases within major MSM-associated S. sonnei and S. 
flexneri lineages, it is plausible that MSM lineages were imported into Australia, with subsequent 
onwards transmission in the context of a successful epidemiological triad of host (dense MSM 
networks with high-risk sexual behaviours), pathogen (highly infectious bacterial species with 
transmissible resistance determinants) and environment (selection pressure from azithromycin use).  
Indeed, many isolates in the Australian S. flexneri 2a MSM-associated lineage were highly related at a 
core genome level to isolates from a previous UK study [10], further highlighting the importance of 
global travel in propagating shigellosis outbreaks.  Moreover, the hypothesis of importation and 
domestic spread of pathogens in MSM is also supported by recent outbreaks of other pathogens, such 
as hepatitis A virus [40] and azithromycin-resistant Neisseria gonorrhoeae [41], demonstrating the 
need for improved understanding of the factors that may promote such outbreaks, such as HIV co-
infection, pre-exposure prophylaxis, asymptomatic carriage, and circumstantial features such as social 
networking applications and recreational drug use. 
 
In addition to MSM-associated shigellosis, the other major burden of disease in our study was 
amongst returning travellers. Previous work from the UK has demonstrated travel-associated Shigella 
sub-lineages, with distinct phylogeographic associations [9].  Here, we broaden this genomic 
framework extensively to include isolates from returned travellers in Australia. Like the UK study, we 
observed similar patterns of triple QRDR mutations in Shigella isolates from Southern Central Asia 
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(mainly India, Pakistan and Nepal), and South-East Asia (mainly Vietnam and Cambodia) further 
highlighting these regions as reservoirs of resistant enteric pathogens [12],  a situation that has 
parallels with the global emergence of fluoroquinolone-resistant Salmonella Typhi [42]. Our study 
further demonstrates the utility of genomic surveillance in detecting emerging genotypic AMR 
patterns, using isolates from returned travellers as a proxy for assessing AMR in other regions.  
 
Key strengths of our study include our contemporary sampling frame (i.e. 2016 – 2018); 
comprehensive coverage of cultured cases of shigellosis, and integration of detailed epidemiological 
data.  Further, previous studies have demonstrated high interconnectivity of MSM populations in 
urban Australia [43], meaning that our findings are likely to have applicability across major cities in 
Australia.  Moreover, the inclusion of epidemiologically relevant international isolates provides 
additional geographic context  [9, 10, 13].  
 
Although we received all cultured isolates in the state during the study, this represented only 43% of 
shigellosis notifications over the study period.  This limitation applies to all WGS-based studies of 
shigellosis, whereby the increasing use of molecular testing for enteric pathogens reduces the 
availability of isolates for additional analyses [44]. This situation has marked parallels with the use of 
molecular testing for N. gonorrhoeae, where reduced bacterial culture is compromising the ability to 
detect multi-resistant isolates [45].  In an era of increasing AMR in STIs, it is critical that concerted 
efforts are made to ensure continuation of culture-based surveillance. 
 
In conclusion, we present to our knowledge, the first population-based genomic surveillance of 
shigellosis in Australia.  We demonstrate the global dissemination of a multi-resistant plasmid, 
present across multiple continents, and highly associated with MSM. This represents a significant and 
immediate health threat not only in Australia, but also globally. Urgent multidisciplinary public health 
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measures are required, including enhanced contact tracing of multi-resistant cases of shigellosis 
(which could be informed by WGS data), improved antimicrobial stewardship, improved information 
on clinical outcomes of resistant shigellosis, and heightened awareness of shigellosis as an STI. 
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FIGURE LEGENDS 
 
Figure 1. Population structure of 364 Australian Shigella sonnei isolates included in this study. The 
mid-point rooted phylogenetic tree of Shigella sonnei is plotted on the left. A total of 16 additional 
representative genomes are included to provide reference to established population structure [29]. The 
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tips are colored by primary risk factor. BAPs groups are highlighted. Phenotypic resistance profiles 
are shown next to corresponding genotypic mutations for ciprofloxacin (number of QRDR mutations; 
see text), azithromycin (mphA), trimethoprim (any dfr mutation) and sulfonamides (any sul mutation).  
In addition, the effect of reducing the ciprofloxacin breakpoint to 0.12 g/mL is displayed (‘high 
resistance potential’; HRP). 
 
Figure 2. Population structure of 171 Australian Shigella flexneri isolates and 20 additional 
representative genomes are included to provide reference to established population structure [28]. The 
mid-point rooted phylogenetic tree of Shigella flexneri is plotted on the left. The tips are colored by 
primary risk factor. BAPs groups are highlighted. Phenotypic resistance profiles are shown next to 
corresponding genotypic mutations for ciprofloxacin (number of QRDR mutations; see text), 
azithromycin (mphA), trimethoprim (any dfr mutation) and sulfonamides (any sul mutation).  In 
addition, the effect of reducing the ciprofloxacin breakpoint to 0.12 g/mL is displayed (‘high 
resistance potential’; HRP). 
 
Figure 3. Comparison of four Australian pKSR100-like plasmids with pKSR100 (SF7955). 
The structure of the pKSR100 plasmid is shown at the bottom of each panel with the comparison 
plasmid at the top. A) S. flexneri 1c strain AUSMDU00008355 (BP1 lineage); B) S. flexneri 2a strain 
AUSMDU00008332 (BP2 lineage); C) S. sonnei biotype g strain AUSMDU00008333 (BP1 lineage) 
and D) S. sonnei biotype g strain AUSMDU00008361 (BP3 lineage). Plasmid genes are shown in 
orange with genes mediating resistance to different drug classes highlighted in: green (blaTEM-1), 
purple (mphA and ermB) and blue for (dfrA17, sul1 and aadA). The shaded grey indicates regions 
with nucleotide homology of ≥90 percent of higher. 
 
Figure 4. Dissemination of multi-drug resistant plasmid within and between Shigella spp.  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz005/5274662 by London School of H
ygiene & Tropical M
edicine user on 18 January 2019
  23 
A. Comparisons of plasmids detected in four Australian Shigella isolates. Plasmid genes are shown in 
orange with genes mediating resistance to different drug classes highlighted in: (i) green for blaTEM-1, 
(ii) purple for mphA and ermB and (iii) blue for dfrA17, sul1 and aadA. The shaded grey indicates 
sequence homology regions of ≥90 percent of higher. B) The inferred phylogeny of pKSR100-like 
plasmids within S. flexneri and S. sonnei of isolates that had ≥90% of nucleotide coverage to the 
pKSR100 reference. The primary risk factor, the species membership and serotype for the isolates are 
shown to the right of the phylogeny. The Shigella species of an isolate is plotted to the right of the 
phylogeny. A binary heatmap illustrates the presence/absence of six genes known to be mobilized on 
the pKSR100-like plasmids. 
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Table 1. Characteristics of Shigella sonnei isolates included in this study and associations with phylogenetic groupings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic BAPS group 
a 
 
P 
b 
BP1 BP2 BP3 BP4
 
Median pairwise SNP difference (IQR) 50 (41-75) 168 (144-189) 4 (2-6) 106 (64-120)  
Phenotypic resistance Number resistant / isolates tested (% resistant)  
Ampicillin 37/98 (37.8) 10/40 (25) 150/159 (94.3) 11/57 (19.3) <0.001 
Ciprofloxacin (CIP) 75/98 (76.5) 0/40 2/159 (1.3) 1/57 (1.8) <0.001 
Azithromycin (AZT) 27/98 (27.6) 0/40 148/159 (93.1) 6/57 (10.5) <0.001 
Ceftriaxone 19/98 (19.4) 0/40 11/159 (6.9) 5/57 (8.8) 0.002 
Trimethoprim (TMP) 97/98 (99.0) 26/40 (65.0) 159/159 (100) 57/57 (100) <0.001 
Sulfathiozole (SUL) 86/98 (87.8) 27/40 (67.5) 157/159 (98.7) 44/57 (77.2) <0.001 
Gentamicin 3/97 (3.1) 0/40 0/159 1/57 (1.8) 0.13 
Meropenem 2/98 (2.0) 1/40 (2.5) 1/159 (0.6) 0/57 NA 
Resistant to 2 oral antimicrobials 71/98 (72.4) 0/40 (0) 147/159 (92.4) 6/57 (10.5) <0.001 
Resistant to 3 oral antimicrobials 22/98 (22.4) 0/40 (0) 2/159 (1.3) 1/57 (1.8) <0.001 
‘High resistance potential’ for ciprofloxacin 82/88 (93.2) 0/39 (0) 147/149 (98.6) 12/52 (23.1) <0.001 
Epidemiological characteristic      
Males 54/102 (52.0) 17/40 (42.5) 144/159 (90.6) 25/57 (43.8) <0.001 
Median age (IQR) 28.5 (10.5-43) 36.5 (25.25-44.75) 38 (30-48) 34 (24-55) <0.001 
Overseas travel or contact with traveller 62/102 (60.7) 25/40 (62.5) 12/159 (7.6) 39/57 (68.4) <0.001 
Male to male sexual contact 8/102 (7.8) 3/40 (7.6) 97/159 (61.0) 2/57 (3.5) <0.001 
Other / unknown 32/102 (31.3) 12/40 (30.0) 50/159 (31.4) 16/57 (28.1) 0.49 
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Abbreviations: SNP, single nucleotide polymorphism; IQR, interquartile range; BAPS, Bayesian Analysis of Population Structure; BP, BAPS group; NA, not applicable 
a 
Four isolates that belonged to a divergent group (BP5) were excluded from this analysis (see text). Two Australian isolates initially identified as BP4 were also excluded 
from the BP4 analysis. 
b 
2 x 4 2 test 
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Table 2. Characteristics of Shigella flexneri isolates included in this study and associations with phylogenetic groupings. 
 
Characteristic BAPS group 
a 
P
 a 
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Abbreviations: SNP, single nucleotide polymorphism; IQR, interquartile range; BAPS, Bayesian Analysis of Population Structure; BP, BAPS group; NA, not applicable 
a
 Seven isolates that belonged to divergent group (BP5) were excluded from this analysis (see text). Ten isolates that belonged to distant serotype 6 were also excluded. 
b 
2 x 4 2 test 
 
BP1 BP2 BP3 BP4 
Median pairwise SNP difference (IQR) 162 (125-181) 139 (6-283) 91 (70.25-615) 259 (118.25-325.75)  
Phenotypic resistance Number resistant / isolates tested (% resistant)  
Ampicillin 26/32 (81.3) 102/105 (97.1) 15/16 (93.8) 6/10 (60.0) <0.001 
Ciprofloxacin 2/32 (6.3) 12/105 (11.4) 0/16 (23.5) 2/10 (20.0) 0.30 
Azithromycin 12/32 (37.5) 74/105 (70.5) 6/16 (37.5) 0/10 (0) <0.001 
Ceftriaxone 0/32 (0) 1/105 (1.0) 0/16 (0) 0/10 (0) 0.86 
Trimethoprim 24/32 (75.0) 92/105 (87.6) 2/16 (12.5) 7/10 (70.0) <0.001 
Sulfathiozole 20/32 (62.5) 67/105 (63.8) 3/16 (18.6) 6/10 (60.0) 0.008 
Gentamicin 1/32 (3.1) 0/105 (0) 0/16 (0) 0/10 (0) 0.25 
Meropenem 0/32 (0) 0/105 (0) 0/16 (0) 0/10 (0) NA 
Resistant to 2 oral antimicrobials 13/32 (40.6) 58/105 (55.2) 0/16 (0) 2/10 (20.0) <0.001 
Resistant to 3 oral antimicrobials 0/32 (0)  1/105 (1.0) 0/16 (0) 0/10 (0) 0.91 
‘High resistance potential’ for ciprofloxacin 18/29 (62.1) 14/97 (14.4) 0/15 (0) 6/10 (60.0) <0.001 
Epidemiological characteristic      
Males 25/32 (78.1) 89/105 (84.8) 13/16 (81.3) 5/10 (50.0) 0.001 
Median age (IQR) 39 (30.25-47.75) 37 (28-50) 35.5 (30.25-49.25) 30 (7.25-38) 0.19 
Overseas travel or contact with traveller 11/32 (34.4) 19/105 (18.0) 6/16 (37.5) 6/10 (60.0) 0.008 
Male to male sexual contact 7/32 (21.9) 52/105 (49.5) 6/16 (37.5) 1/10 (10.0) 0.003 
Other / unknown 14/32 (43.8) 34/105 (32.4) 4/16 (25.0) 3/10 (30.0) 0.05 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz005/5274662 by London School of H
ygiene & Tropical M
edicine user on 18 January 2019
